Observational study of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer

Autor:	Hans Petter Eikesdal, Marianne Ewertz, Sajitha Rajendiran, Lars Ottestad, Line Fronth, Liv Hege Aksnes, Egil S. Blix
Rok vydání:	2019
Předmět:	Oncology medicine.medical_specialty Receptors Progesterone/metabolism Receptor ErbB-2 Receptor ErbB-2/metabolism Breast Neoplasms chemistry.chemical_compound Exemestane Breast Neoplasms/drug therapy Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Radiology Nuclear Medicine and imaging Androstadienes/administration & dosage Phosphatidylinositol Everolimus/administration & dosage Everolimus Receptor Survival rate PI3K/AKT/mTOR pathway Aged Aged 80 and over business.industry Cancer Hematology General Medicine Middle Aged medicine.disease Prognosis Androstadienes Postmenopause Survival Rate chemistry Receptors Estrogen Hormone receptor Female Antineoplastic Combined Chemotherapy Protocols/therapeutic use Receptors Estrogen/metabolism business Receptors Progesterone medicine.drug Follow-Up Studies
Zdroj:	Ottestad, L, Fronth, L, Rajendiran, S, Hege Aksnes, L, Eikesdal, H P, Støre Blix, E & Ewertz, M 2019, ' Observational study of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer ', Acta Oncologica, vol. 58, no. 3, pp. 385-387 . https://doi.org/10.1080/0284186X.2019.1566771
ISSN:	1651-226X
DOI:	10.1080/0284186X.2019.1566771
Popis:	To the editor,Aberrant signaling through the phosphatidylinositol 3-kinase (PI3K)-Akt-mammalian target of rapamycin (mTOR) pathway is a well-known mechanism of resistance to endocrine therapy in pa...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38fd880506ec3213ff609b45eaf861ad https://pubmed.ncbi.nlm.nih.gov/30798641 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.